secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059485
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q1 net loss $18.0M, cash $175.2M; key clinical data expected mid-2024
----------------------------------------------------------------------------

- Cash and marketable securities $175.2M as of March 31, 2024, funding operations into 2026.
- Net loss widened to $18.0M from $16.3M YoY; R&D expense $14.7M, G&A $5.1M.
- Preliminary CONNECT1-EDO51 data (5 mg/kg dose) expected mid-2024; FDA orphan/rare pediatric designations granted.
- FREEDOM1-DM1 preliminary data from at least 5 mg/kg cohort expected second half 2024.
- Raised $86.3M net from February common stock offerings (ATM + underwritten).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024059485/0000950170-24-059485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024059485/pepg-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer